Serial No.: 10/589,144 Date Filed: July 12, 2007

Page 2

What is claimed is:

- 1. (original) A composition, comprising:
 a plurality of double-stranded RNA (dsRNA) fragments having
 overlapping sequences, each fragment having a size in the range of
 18-30 nt, wherein the composition is formed by enzymatic digestion of
 one or more large dsRNAs and wherein less than 2nM of the
 composition is capable of specifically silencing expression of a target
- 2. (original) A composition according to claim 1, wherein the composition is capable of specifically silencing target gene expression by 70%.

gene by at least 65% in transfected COS cells.

- 3. (original) A composition according to claim 1, wherein the composition is capable of specifically silencing target gene expression by 80%.
- 4. (original) A composition according to claim 1, wherein the dsRNA has a size of at least 100 nt in length.
- 5. (original) A composition according to claim 1, wherein the plurality of fragments is at least 5 fragments.
- 6. (original) A composition according to claim 1, wherein the plurality of fragments is at least 10 fragments.
- 7. (original) A composition according to claim 1, wherein the large dsRNA has a sequence identity with a first portion of a messenger RNA

Serial No.: 10/589,144 Date Filed: July 12, 2007

Page 3

(mRNA) sequence such that the plurality of dsRNA fragments derived therefrom has a greater gene silencing activity at less than 2nM than a second plurality of fragments having sequence identity with a second portion of the mRNA.

- 8. (original) A composition according to claim 1, wherein the plurality of dsRNA fragments have a greater gene silencing activity at a concentration of less than 2nM than any single fragment in the composition.
- 9. (original) A composition according to claim 1, wherein the enzymatic digestion is achieved using RNaseIII in a manganese buffer or a mutant RNaseIII.
- 10. (original) A composition according to claim 1, wherein the target gene encodes Erk1 or Erk2 and the large dsRNA has sequence identity with a portion of mRNA transcribed from the gene.
- 11. (original) A composition according to claim 1, wherein the target gene encodes Ffluc or Renilla luciferase and the large dsRNA has sequence identity with a portion of mRNA transcribed from the gene.
- 12. (original) A composition according to claim 1, wherein the fragments are derived from digestion of a plurality of dsRNAs and wherein the plurality of dsRNA have sequence identity with noncontiguous regions of the mRNA.
- 13. (original) A composition according to claim 1, wherein the fragments are derived from digestion of a plurality of dsRNA wherein

Serial No.: 10/589,144 Date Filed: July 12, 2007

Page 4

the plurality of dsRNA has sequence identity with contiguous regions of the mRNA.

- 14. (original) A composition according to claim 1, wherein 1nM of the composition is capable of silencing gene expression by at least 70%.
- 15. (withdrawn) A method of preparing a composition described in claim 1, comprising:
- (a) transcribing at least one RNA molecule having a sequence identity with a portion of a target gene, to form a large dsRNA;
- (b) cleaving the large dsRNA into a mixture of overlapping fragments having a size in the range of 18-30 nt by means of RNaseIII or mutants thereof;
- (c) determining whether less than 2nM of the large dsRNA can silence at 65% of gene expression of the target gene in COS cells after transfection; and
 - (d) obtaining the composition described in claim 1.
- 16. (withdrawn) A method of silencing gene expression; comprising:
- (a) cleaving with an enzyme, a large dsRNA having sequence identity with a target gene, wherein the enzyme is RNaseIII or a mutant thereof and the cleavage product is a set of overlapping fragments of dsRNA in which greater than 80% of the fragments have a size of less than about 40nt;

Serial No.: 10/589,144 Date Filed: July 12, 2007

Page 5

- (b) transfecting cells with the cleavage product of step (a) without size fractionating the product; and
- (c) obtaining at least 65% silencing of expression of the target gene.
- 17. (withdrawn) A method according to claim 16, wherein step (b) further comprises: transfecting cells with less than 2nM of the cleavage product of step (a).
- 18. (withdrawn) A method according to claim 16, wherein RNase III cleavage is achieved in the presence of manganese buffer.